epirubicin hydrochloride injection solution
sandoz canada incorporated - epirubicin hydrochloride - solution - 2mg - epirubicin hydrochloride 2mg - antineoplastic agents
epirubicin hydrochloride injection solution
omega laboratories limited - epirubicin hydrochloride - solution - 2mg - epirubicin hydrochloride 2mg - antineoplastic agents
pms-epirubicin solution
pharmascience inc - epirubicin hydrochloride - solution - 2mg - epirubicin hydrochloride 2mg - antineoplastic agents
epirubicin hydrochloride injection solution
strides pharma canada inc - epirubicin hydrochloride - solution - 2mg - epirubicin hydrochloride 2mg - antineoplastic agents
carboplatin- carboplatin injection, solution
sandoz inc - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin 10 mg in 1 ml - carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor <2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. carboplatin is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with c
regurin xl 60mg capsules
viatris uk healthcare ltd - trospium chloride - modified-release capsule - 60mg